SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as the market reacts to a landmark joint venture between AT&T, Verizon, and T-Mobile to expand direct-to-device satellite connectivity, fueling speculation that ASTS will serve as the essential infrastructure layer for these major carriers. While the stock experiences high volatility, the community is actively debating the significance of these carrier partnerships and the potential for a major short squeeze as investors look ahead to upcoming satellite launch milestones.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors prepare for pivotal extended Phase 3 data for CAN-2409, with the community closely monitoring the upcoming plenary presentation for evidence of practice-changing efficacy in prostate cancer. Market participants are actively discussing the stock's significant institutional support, potential for a premium buyout by Big Pharma, and the ongoing tension between optimistic long-term holders and aggressive short-selling activity.

Trio-Tech International engages in the provision of third-party semiconductor testing and burn-in services. It operates through the following segments: Semiconductor Back-End Solutions (SBS) and Industrial Electronics. The SBS segment is focused on the sale of burn-in and reliability test equipment used in the back-end manufacturing processes of semiconductors. Its equipment includes burn-in systems, burn-in boards, and related equipment that is used in the testing of structural integrity of integrated circuits. The Industrial Electronics segment consists of designing, manufacturing, and distributing a range of tests, processes, and other equipment used in the manufacturing processes of customers in various industries in the consumer and industrial market. The company was founded in 1958 and is headquartered in Los Angeles, CA.

Trio-Tech International

Trio-Tech International is trending as investors pivot from story-driven AI names to companies with verifiable semiconductor revenue, with many drawing favorable valuation comparisons to industry peers despite its smaller market cap. The community is actively discussing its potential for a re-rating, fueled by expanding AI and EV testing demand and a lean share structure that amplifies volatility.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending as the community actively discusses the stock's recent GPO partnership and potential for commercial traction, while weighing these developments against persistent concerns regarding management's history of dilution and the company's capital burn. Investors are closely monitoring weekly prescription data and upcoming earnings reports, debating whether current commercial progress justifies the stock's valuation or indicates continued financial instability.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors react to strong earnings and raised EBITDA guidance, while the community actively discusses the stock's significant long-term growth potential and its strategic importance in the ongoing global LNG supply disruption. Traders are closely monitoring the impact of Middle East geopolitical tensions and potential price target upgrades as they anticipate a breakout beyond current resistance levels.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors aggressively debate whether the current price represents a deep-value accumulation opportunity or a value trap, with community sentiment split between frustration over persistent share price weakness and conviction in the company's pivot toward agentic AI orchestration. Traders are closely monitoring a high level of short interest and significant institutional accumulation, viewing upcoming earnings as a critical catalyst to potentially break the stock out of its long-standing consolidation phase.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is capturing significant investor attention following a robust quarterly performance that exceeded revenue and profit expectations, driven by the strong adoption of its oral Wegovy GLP-1 therapy. The community is actively discussing this momentum as a potential reversal of previous growth concerns, while also tracking high-volume prescription data and competitive dynamics against Eli Lilly.

SolarEdge Technologies, Inc. engages in the development of energy technology, which provides inverter solutions. The firm operates through the following segments: Solar and All Other. The Solar segment includes the design, development, manufacturing, and sales of an inverter solution designed to maximize power generation. The All Other segment includes the design, development, manufacturing and sales of UPS products, energy storage products, e-Mobility products, and automated machines. Its products and services include photovoltaic inverters, power optimizers, photovoltaic monitoring, software tools, and electric vehicle chargers. The company was founded by Guy Sella, Lior Handelsman, Yoav Galin, Meir Adest, and Amir Fishelov on August 7, 2006 and is headquartered in Herzliya, Israel.

Solaredge Technologies Inc

SolarEdge is experiencing significant market volatility driven by speculative options trading and broader energy sector reactions to shifting geopolitical tensions and AI-driven data center demand. Investors remain sharply divided, with a vocal community debating the stock's long-term turnaround potential versus concerns over sustained cash burn and competitive pressure.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is experiencing intense volatility and heavy algorithmic manipulation despite reporting strong earnings and growth metrics that have led analysts to maintain high price targets. The community is actively debating the stock's disconnect between its robust fundamental performance and its erratic price swings, with many investors viewing the current price action as a strategic shakeout by institutional players ahead of potential platform catalysts.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is under intense selling pressure as persistent inflation concerns and surging crude oil prices drive Treasury yields to multi-year highs. The community is actively debating whether current support levels will hold or if mounting fiscal debt and a hawkish interest rate environment will trigger a deeper structural breakdown in the bond market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL.

ATXI
Avenue Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest ATXI News

ATXIAvenue Therapeutics Inc